Description: Merus B.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, colorectal, and ovarian cancers. The company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies. Its pre-clinical bispecific antibody candidates include MCLA-134, MCLA-114, and MCLA-145, as well as other early research projects. The company has a strategic collaboration with Gustave Roussy to develop innovative bispecific antibodies for therapeutic immuno-oncology applications. Merus B.V. was founded in 2003 and is headquartered in Utrecht, the Netherlands.
Home Page: www.merus.nl
MRUS Technical Analysis
Yalelaan 62
Utrecht,
3584 CM
Netherlands
Phone:
31 30 253 8800
Officers
| Name | Title |
|---|---|
| Dr. Sven Ante Lundberg M.D. | CEO, Pres, Principal Financial Officer & Exec. Director |
| Mr. Peter B. Silverman J.D. | Exec. VP, Gen. Counsel, Chief Intellectual Property Officer and Head of Utrecht & US Legal |
| Mr. Hui Liu Ph.D. | Chief Bus. Officer, Exec. VP & Head of Merus U.S. |
| Dr. Hennie Hoogenboom | Co-Founder and Scientific Advisor |
| Harry Shuman | Chief Accounting Officer |
| Mr. Cornelis Adriaan de Kruif Ph.D. | CTO & Exec. VP |
| Dr. Cecilia Anna Wilhelmina Geuijen Ph.D. | Chief Scientific Officer & Sr. VP |
| Ms. Jillian Connell | VP of Investor Relations & Corp. Communications |
| Mr. Alexander Berthold Hendrik Bakker Ph.D. | Chief Devel. Officer & Exec. VP |
| Dr. Andrew Joe M.D. | Chief Medical Officer & Sr. VP |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.1479 |
| Price-to-Sales TTM: | 13.1869 |
| IPO Date: | 2016-05-19 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |